Otsuka deal a salve for BMS
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical and Bristol-Myers Squibb have extended their 1999 US agreement for Abilify (aripiprazole) until the product's expected loss of exclusivity in April 2015.